* Calithera Biosciences Inc CALA.OQ CALA.O is expected
to show
a fall in quarterly revenue when it reports results on November
14.
*
* Refinitiv's mean analyst estimate for Calithera
Biosciences Inc
is for a loss of $1.93 per share.
* The current average analyst rating on the shares is
"strong buy"
and the breakdown of recommendations is 3 "strong buy" or
"buy," no "hold" and no "sell" or "strong sell."
* The mean earnings estimate of analysts was unchanged in
the last
three months.
* Wall Street's median 12-month price target for Calithera
Biosciences Inc is $17, above its last closing price of $2.55.
Previous quarterly performance (using preferred earnings measure
in US dollars).
QUARTER STARMINESM REFINITIV ACTUAL BEAT, SURPRI
ENDING ARTESTIMAT IBES MET, SE %
E® ESTIMATE MISSED
Jun. 30 2022 -2.66 -2.65 -1.59 Beat 40.1
Mar. 31 2022 -3.85 -3.70 -3.60 Beat 2.7
Dec. 31 2021 -5.30 -4.80 -4.80 Met 0
Sep. 30 2021 -4.42 -4.56 -3.00 Beat 34.2
Jun. -4.77 -4.81 -3.80 Beat 20.9
30 2021
Mar. 31 2021 -5.37 -5.52 -5.60 Missed -1.4
Dec. 31 2020 -6.60 -6.48 -6.40 Beat 1.2
Sep. 30 2020 -6.26 -6.21 -6.40 Missed -3.1
This summary was machine generated November 11 at 22:35 GMT.
All figures in US dollars unless otherwise stated